COMPASS Pathways   Report issue

For profit Phase 3
Founded: London United Kingdom (2016)

Organization Overview

First Clinical Trial
2018
NCT03775200
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

COMPASS Pathways

Active Ingredients

Drugs in Phase 3 Trials (1)

psilocybin (13 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Anorexia Nervosa (Phase 2)

Bipolar Disorder (Phase 2)

Body Dysmorphic Disorders (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 1